Jim Cornall is the Editor In Chief at Labiotech.eu. He specializes in topics related to biotech, including the impact of AI and the FDA, as well as covering the latest developments in podcasts and the ongoing implications of the Coronavirus. Jim's insights and expertise have been featured in various reputable publications, including Labiotech.eu.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Jim's coverage primarily focuses on the healthcare and pharmaceutical industries, with a significant emphasis on biotechnology. He frequently cites data and press releases, indicating an interest in factual information and industry developments.
Given his focus on specific companies, scientific advancements, and medical breakthroughs, Jim is likely to be responsive to experts who can provide insights into cutting-edge research or innovations in biotechnology, drug discovery, medical research or clinical trials.
If you have access to exclusive data or expert analysis related to new products or scientific discoveries within the healthcare and biotech sectors that align with Jim's coverage themes, it is more likely to capture his attention.
This information evolves through artificial intelligence and human feedback. Improve this profile .
This week on our podcast, explore how precision neuromedicine is reshaping neurological care with Rapport Therapeutics.
Tome Biosciences recently exited stealth mode with almost a quarter of a billion dollars in funding.
Immunai is using artificial intelligence to map the immune system. The company hopes this will lead to better and faster drug discovery.
By: Jim Cornall
There is a clear demand for novel, neurological treatments. While it's widely known psychedelics hold enormous therapeutic potential, there are a
Explore the latest strides in schizophrenia treatment development as 2024 heralds a pivotal year, with promising collaborations and trials.
By: Jim Cornall
Based in Austin, Texas , biotech Colossal Biosciences is at the forefront of de-extinction, critically endangered species protection and the repopulation of critical ecosystems.
Doloromics is a precision neuropharmaceuticals company. It was set up four years ago, to use newer technologies, particularly in the omics space, to
Dive into 2024's biotech investment strategies with RTW Investments on our podcast. Discover trends shaping the landscape ahead.
By: Jim Cornall
Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class
By: Jim Cornall
German-headquartered Isarna Therapeutics is developing a portfolio of antisense therapies targeting an emerging therapeutic field in human biology – transforming growth factor beta (TGF-B) signaling.
(833) 317-6278 
